Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Amgen Inc (NASDAQ:AMGN)

173.29
Delayed Data
As of Feb 17
 +1.18 / +0.69%
Today’s Change
133.64
Today|||52-Week Range
176.85
+18.52%
Year-to-Date
The Four Key Themes From Q4 Conference Calls
Feb 17 / Investing Channel - Paid Partner Content
Marco Investment Management Llc Buys Johnson Controls International PLC, Amgen, AbbVi...
Feb 16 / GuruFocus News - Paid Partner Content
Mylan's Proposed Biosimailar for Cancer Under Review in U.S.
Feb 17 / Zacks.com - Paid Partner Content
Amgen Shows a Bullish Breakout
Feb 16 / TheStreet.com - Paid Partner Content
Valeant's (VRX) Plaque Psoriasis Drug Approved in the U.S.
Feb 17 / Zacks.com - Paid Partner Content
Health Care ETF Has Been Ailing
Feb 16 / TheStreet.com - Paid Partner Content
Pfizer's Xeljanz Combo Comparable to AbbVie's Humira
Feb 17 / Zacks.com - Paid Partner Content
Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback
Feb 16 / Zacks.com - Paid Partner Content
Don't Count on Valeant's New Drug to Save the Day
Feb 16 / MotleyFool.com - Paid Partner Content
Samlyn Capital, Llc Buys TD Ameritrade Holding, American Express Co, Comerica, Sells ...
Feb 15 / GuruFocus News - Paid Partner Content

Today’s Trading

Previous close172.11
Today’s open171.35
Day’s range168.89 - 173.36
Volume4,154,875
Average volume (3 months)3,952,400
Market cap$127.6B
Dividend yield2.65%
Data as of 4:14pm ET, 02/17/2017

Growth & Valuation

Earnings growth (last year)+13.02%
Earnings growth (this year)+6.49%
Earnings growth (next 5 years)+7.78%
Revenue growth (last year)+7.76%
P/E ratio17.3
Price/Sales4.80
Price/Book4.28

Competitors

 Today’s
change
Today’s
% change
GILDGilead Sciences-0.46-0.65%
BIIBBiogen-1.19-0.41%
ILMNIllumina Inc+2.07+1.28%
BIVVBioverativ Inc+3.35+7.60%
Data as of 4:14pm ET, 02/17/2017

Financials

Next reporting dateApril 25, 2017
EPS forecast (this quarter)$2.99
Annual revenue (last year)$23.0B
Annual profit (last year)$7.7B
Net profit margin33.59%

Profile

Sector
Health Technology
Industry
Biotechnology
Chairman &
Chief Executive Officer
Robert A. Bradway
Executive Vice President-
Operations
Esteban Santos
Corporate headquarters
Thousand Oaks, California

Forecasts


Search for Jobs